Pfizer beats profit estimates on strong demand for new drugs
on Tuesday reported first-quarter profit that beat Wall Street estimates, as strong demand for its recently acquired products and pneumococcal vaccines helped offset the impact from declining sales of its COVID-19 products. Excluding items, the U.S. drugmaker earned $1.23 per share for the quarter…#pfizerinc #refinitiv #bhanvisatija #raghavmahobe #bengaluru #srirajkalluvila (Source: Reuters: Health)
Source: Reuters: Health - May 2, 2023 Category: Consumer Health News Source Type: news
U.S. FDA Approves Prevnar 20, Pfizer ’s 20-Valent Pneumococcal Conjugate Vaccine for Infants and Children
NEW YORK--(BUSINESS WIRE) April 27, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Prevnar 20®(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 27, 2023 Category: Drugs & Pharmacology Source Type: news
U.S. FDA approves PREVNAR 20 ®, Pfizer's 20-valent pneumococcal conjugate vaccine for infants and children
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20®(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in PREVNAR®. (Source: World Pharma News)
Source: World Pharma News - April 27, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
U.S. FDA approves PREVNAR 20 ®, Pfizer & #039;s 20-valent pneumococcal conjugate vaccine for infants and children
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20®(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in PREVNAR®. (Source: World Pharma News)
Source: World Pharma News - April 27, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
ACIP 2023 Recommended Immunization Schedule for Adults ACIP 2023 Recommended Immunization Schedule for Adults
Review vaccine-specific changes in the 2023 immunization schedule for adults aged 19 years and older, including updates to influenza, hepatitis B, and pneumococcal vaccination.Morbidity & Mortality Weekly Report (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 24, 2023 Category: Infectious Diseases Tags: Public Health & Prevention Journal Article Source Type: news
Pneumonia vaccine trial data sends Peninsula biotech stock higher
The company's vaccine would offer protection against 24 varieties of the bacterium responsible for invasive pneumococcal diseases. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 17, 2023 Category: Biotechnology Authors: Ron Leuty Source Type: news
Meningococcal Vaccine Shows Benefit in STI Prevention Meningococcal Vaccine Shows Benefit in STI Prevention
A new trial looks at the effect of doxycycline post-exposure prophylaxis and vaccination with meningococcal B vaccine on rates of sexually transmitted infections in men who have sex with men.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 22, 2023 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
AAP Approves 2023 Child and Adolescent Immunization Schedule AAP Approves 2023 Child and Adolescent Immunization Schedule
Minor changes and additions to annual ACIP recommendations affected vaccines for COVID-19; dengue fever; pneumococcal disease; and measles, mumps, and rubella.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 9, 2023 Category: Allergy & Immunology Tags: Pediatrics News Source Type: news
MenACWY risk groups: patient group direction template (update)
This supports the provision of meningococcal group A, C, W and Y conjugate vaccine to individuals with underlying medical conditions. It has been updated to include particulars pertaining to an additional licensed vaccine (MedQuadfi ® ), with minor rewording/formatting changes.
2 February 2023Added version 04.00, see page 2 for changes.
15 February 2021Added updated PGD: v3.00. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 6, 2023 Category: Consumer Health News Source Type: news
4CMenB Vaccination Effective Against Invasive Meningococcal Disease in Children Under 5
THURSDAY, Feb. 2, 2023 -- Complete vaccination with the four-component, protein-based meningococcal serogroup B vaccine (4CMenB) is effective for preventing invasive meningococcal disease in children younger than 5 years, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 2, 2023 Category: Pharmaceuticals Source Type: news
Meningococcal Vaccine 76% Effective for Kids Under 5, Study Says
(MedPage Today) -- Complete vaccination with the four-component, protein-based meningococcal serogroup B vaccine (4CMenB; Bexsero) was found to be effective in the prevention of invasive serogroup B and non-serogroup B disease among children younger... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 1, 2023 Category: American Health Source Type: news
DHS Announces Immunization Updates for Children in Child Care Centers and Schools
The Wisconsin Department of Health Services (DHS) has announced updates to the immunizations needed for children in child care centers and schools. The changes include updated requirements related to meningitis and whooping cough immunizations, and that past chickenpox infection must be documented by a qualified medical professional. There is no change to existing exemption options for medical, religious, or philosophical reasons. Seasonal flu vaccination or COVID-19 vaccination are not required...(see release)JenniferC.MillerFebruary 1, 2023 (Source: Wisconsin DHFS Press Releases)
Source: Wisconsin DHFS Press Releases - February 1, 2023 Category: Hospital Management Authors: JenniferC.Miller Source Type: news
Fears as life-saving meningitis vaccine is 'canceled for commercial reasons'
Since meningitis vaccines were introduced in 1999, yearly cases have dropped from about 1,300 to just a handful. Now, health chiefs said they will remove it from the childhood immunisation schedule. (Source: the Mail online | Health)
Source: the Mail online | Health - January 28, 2023 Category: Consumer Health News Source Type: news
Pneumococcal disease infections caused by serotypes not in Prevenar 13 vaccine
This document contains 4 graphs showing cumulative weekly reports of invasive pneumococcal disease () caused by serotypes not in .
Data covers these age groups:
under 2s
age 2 to 4 years
age 5 to 64 years
age 65 years or over
Data is:
from June 2006 to now by epidemiological year
from England (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 18, 2023 Category: Consumer Health News Source Type: news
Africa: 8th WHO Technical Taskforce - Defeating Meningitis By 2030 - a Global Road Map
[WHO] The 8th meeting was held from Tuesday 13th - Thursday 15th December 2022, chaired by Professor Brian Greenwood (London School of Hygiene and Tropical Medicine - UK) and Professor Samba Sow (Centre for Vaccine Development - Mali). Some 40 Members and WHO staff discussed global updates, regional and country implementation, operationalizing country support, product development and guidelines, surveillance, the investment case to defeat meningitis, and advocacy activities. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 18, 2023 Category: African Health Source Type: news
